title: Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats.
abstract: Diabetes mellitus is now the most common cause of end-stage renal failure. In this study, the effects of Hachimi-jio-gan on diabetic kidney damage in spontaneously diabetic WBN/Kob rats were examined. Oral administration of Hachimi-jio-gan to WBN/Kob rats for 25 weeks significantly suppressed urinary protein excretion. It did not affect body weight loss or blood glucose levels, whereas it reversed the increase in kidney weight of WBN/Kob rats. Hachimi-jio-gan also reduced fibronectin and transforming growth factor beta1 (TGF-beta1) protein expression in the renal cortex. Furthermore, renal lipid peroxidation levels of WBN/Kob rats given Hachimi-jio-gan were significantly lower than those of untreated controls. Renal superoxide dismutase activity was elevated by Hachimi-jio-gan treatment in a dose-dependent manner. These results suggested that Hachimi-jio-gan could prevent diabetic kidney damage by reducing renal oxidative injury and expression of fibronectin and TGF-beta1 proteins, which are all involved in the pathophysiology of diabetic nephropathy.
authors.affiliation: Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.
authors.forename: Takako
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Takako
authors.initials: T
authors.lastname: Yokozawa
authors.forename: Noriko
authors.initials: N
authors.lastname: Yamabe
authors.forename: Dong Young
authors.initials: DY
authors.lastname: Rhyn
authors.forename: Hirozo
authors.initials: H
authors.lastname: Goto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Shimada
authors.forename: Naotoshi
authors.initials: N
authors.lastname: Shibahara
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000235:genetics; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D005353:Fibronectins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D011919:Rats, Inbred Strains; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D014556:Urine / Q000737:chemistry
chemical_list: D001786:Blood Glucose; D004365:Drugs, Chinese Herbal; D005353:Fibronectins; D017392:Thiobarbituric Acid Reactive Substances; D016212:Transforming Growth Factor beta; C054591:hachimijiogan; D003404:Creatinine; D013482:Superoxide Dismutase